Evidence map›Paper›PMID 29201171›Full record

ArticleExperimental and therapeutic medicine2017

An integrated bioinformatical analysis of miR-19a target genes in multiple myeloma.

Hongyan Lv, Xianda Wu, Guiru Ma, Lixia Sun, Jianbo Meng, Xiaoning Song, Jinqiao Zhang

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Role of miRNA-19a in Cancer Diagnosis and Poor Prognosis.International journal of molecular sciences · 2021
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hongyan LvDepartment of Hematology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China.
Xianda WuDepartment of Hematology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China.
Guiru MaDepartment of Hematology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China.
Lixia SunDepartment of Hematology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China.
Jianbo MengDepartment of Hematology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China.
Xiaoning SongDepartment of Hematology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China.
Jinqiao ZhangDepartment of Hematology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China.
Hebei Medical University · CNThird Hospital of Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA (miR)-19a, as an oncomiR, has been studied in several types of cancer; however, its role in the development and progression of multiple myeloma (MM) remains unclear. The present study used a bioinformatics approach to investigate the involvement of miR-19a in MM. miR-19a targets were predicted using target prediction programs, followed by screening for differentially expressed genes in MM. The function of these genes was then annotated using gene ontology term enrichment, signaling pathway enrichment and protein-protein interaction (PPI) analysis. In addition, natural language processing (NLP) was performed to identify genes associated with MM. A total of 715 putative targets of miR-19a were identified in the present study, of which 40 were experimentally validated. A total of 121 genes were identified to be differentially expressed in MM, including 80 upregulated genes and 41 downregulated genes. Among the differentially expressed genes, ras homolog family member B, clathrin heavy chain, prosaposin and protein phosphatase 6 regulatory subunit 2 were predicted target genes of miR-19a. The results of NLP revealed that 2 of the differentially expressed genes, Y-box binding protein 1 and TP53 regulated inhibitor of apoptosis 1, were reported to be associated with MM. In addition, 41 target genes of miR-19a were identified to be associated with the development and progression of MM. These results may aid in understanding the molecular mechanisms of miR-19a in the development and progression of MM. In addition, the results of the present study indicate that targets genes of miR-19a are potential candidate biomarkers for MM.

Indexed as

gene expressionmiR-19amultiple myelomasystematic analysis

Identifiers

PMID29201171
PMCPMC5704339
OpenAlexW2757431671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.